MCL-553: Glofitamab Induces High Response Rates and Durable Remissions in Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those With a Poor Prognosis: Subgroup Results From a Phase 1/2 Trial
Year: 2025
Type: conference-abstract
Authors: Tycel Phillips, Marek TrnenyMD,, Carmelo Carlo-Stella, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Michael Dickinson, Monica Tani, Michael Crump, Nancy L. Bartlett, Joaquin Martinez-Lopez, Paolo Corradini, Estefania Mulvihill, Alessia Bottos, Derrick Kaufman, James Relf, Fabiola Bene Tchaleu, Alexandra Bazeos, Linda Lundberg, Franck Morschhauser
Institutions: City Of Hope National Medical Center, Charles University, Humanitas University, IRCCS Humanitas Research Hospital, Gdańsk Medical University, Wroclaw Medical University, Ghent University Hospital, Peter MacCallum Cancer Centre, Ospedale "Santa Maria delle Croci" di Ravenna, Princess Margaret Cancer Centre, Washington University in St. Louis, Universidad Complutense de Madrid, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Roche (Switzerland), Genentech, Roche (United Kingdom), Centre Hospitalier Universitaire de Lille
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413774199